Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the worldwide biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
This episode includes insights from around the biopharma world for the business week ended 29 January 2021.
This time we have the latest on Johnson & Johnson’s coronavirus vaccine, Novartis AG’s Q4 results, safety issues around one JAK inhibitor, Eli Lilly and Company’s growth plans, and the latest in the Scrip Asks series.
These and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and now on Spotify Podcasts - and also via smart speakers if one of these channels has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "J&J Forecasts Strong Pharma Growth In 2021, But No COVID-19 Vaccine Update" - Scrip, 26 Jan, 2021.)
(Also see "Novartis Holds Out For Happier Second Half Of 2021" - Scrip, 26 Jan, 2021.)
(Also see "Pfizer's Xeljanz Post-Marketing Study Raises Safety Alarms" - Scrip, 27 Jan, 2021.)
(Also see "CFO Joshua Smiley On Lilly’s Next Decade Of Growth" - Scrip, 22 Jan, 2021.)
(Also see "Scrip Asks…What Does 2021 Hold For Biopharma? Part 2: COVID-19 Shock Waves And Silver Linings" - Scrip, 25 Jan, 2021.)